SG11201808465UA - NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS - Google Patents
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONSInfo
- Publication number
- SG11201808465UA SG11201808465UA SG11201808465UA SG11201808465UA SG11201808465UA SG 11201808465U A SG11201808465U A SG 11201808465UA SG 11201808465U A SG11201808465U A SG 11201808465UA SG 11201808465U A SG11201808465U A SG 11201808465UA SG 11201808465U A SG11201808465U A SG 11201808465UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rue
- pct
- new anti
- sirpa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011111111111110101111101110101111111011111101100111111111110111111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ...... ... WO 2017/178653 A2 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/059071 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, 14 April 2017 (14.04.2017) KP, MD, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, TH, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/322,707 14 April 2016 (14.04.2016) US 17305182.2 17 February 2017 (17.02.2017) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: OSE IMMUNOTHERAPEUTICS [FR/FR]; GM, 22 Bd Benoni Goullin, 44200 NANTES (FR). TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: POIRIER, Nicolas; 1 Chemin du Passe- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Temps, 44119 TREILLIERES (FR). MARY, Caroline; 7 LV, me du Buisson, 44680 SAINTE PAZANNE (FR). VAN- HOVE, Bernard; 72 bis rue Henri Barbusse, 44400 REZE SM, (FR). GAUTTIER, Vanessa; 2, Rue Felicien Thomazeau, GW, KM, ML, MR, NE, SN, TD, TG). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 44400 REZE (FR). THEPENIER, Virginie; 9 Rue des Published: Frenes, 44710 PORT-SAINT-PERE (FR). PENGAM, without international search report and to be republished Sabrina; 15 Rue Guillaume Grootaers, Batiment 5, 44300 upon receipt of that report (Rule 48.2(g)) NANTES (FR). — with Agent: GEVERS & ORES; Association N° 92, 41, aven- sequence listing part of description (Rule 5.2(a)) = (74) ue de Friedland, 75008 PARIS (FR). N M ir) GC IN 11 IN 11 0 \" (54) Title: NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS C ) ,.. (57) : The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322707P | 2016-04-14 | 2016-04-14 | |
| EP17305182 | 2017-02-17 | ||
| PCT/EP2017/059071 WO2017178653A2 (en) | 2016-04-14 | 2017-04-14 | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808465UA true SG11201808465UA (en) | 2018-10-30 |
Family
ID=58185461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808465UA SG11201808465UA (en) | 2016-04-14 | 2017-04-14 | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3443010A2 (en) |
| CN (1) | CN109071664B (en) |
| AU (1) | AU2017248626A1 (en) |
| BR (1) | BR112018070823A2 (en) |
| CA (1) | CA3020373A1 (en) |
| CO (1) | CO2018010855A2 (en) |
| EA (1) | EA201891882A1 (en) |
| PE (1) | PE20181921A1 (en) |
| SG (1) | SG11201808465UA (en) |
| WO (1) | WO2017178653A2 (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3331902T (en) | 2015-08-07 | 2021-07-26 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
| JP7173971B2 (en) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | ANTI-SIRP-α ANTIBODY AND METHOD OF USE THEREOF |
| KR20190117670A (en) * | 2017-02-17 | 2019-10-16 | 오제 이뮈노테라프틱스 | New Uses of Anti-SIRPg Antibodies |
| KR20190140454A (en) | 2017-04-13 | 2019-12-19 | 아두로 바이오테크 홀딩스, 유럽 비.브이. | Anti-SIRP alpha antibody |
| EP3625259B1 (en) | 2017-05-16 | 2024-04-17 | Byondis B.V. | Anti-sirpalpha antibodies |
| MX2020001309A (en) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof. |
| CN111511766A (en) * | 2017-10-13 | 2020-08-07 | Ose免疫疗法 | Modified anti-SIRPa antibody and application thereof |
| JP7035299B2 (en) * | 2017-10-26 | 2022-03-15 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド | New recombinant fusion proteins, as well as their preparation and use |
| JP2021517130A (en) | 2018-03-13 | 2021-07-15 | オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ | Use of anti-human SIRPav1 antibody and method for producing anti-v1 antibody |
| WO2019178218A1 (en) * | 2018-03-14 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Anti-polysialic acid antibodies and uses thereof |
| US11292850B2 (en) * | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| AR115418A1 (en) | 2018-05-25 | 2021-01-13 | Alector Llc | ANTI-SIRPA ANTIBODIES (SIGNAL REGULATING PROTEIN a) AND METHODS OF USE OF THE SAME |
| US20210155707A1 (en) * | 2018-07-10 | 2021-05-27 | National University Corporation Kobe University | ANTI-SIRPalpha ANTIBODY |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| AU2019349651B2 (en) * | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| CA3118326A1 (en) | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
| EP3880239A4 (en) * | 2018-11-14 | 2022-11-23 | Arch Oncology, Inc. | THERAPEUTIC SIRPalpha ANTIBODIES |
| CA3118966A1 (en) | 2018-11-15 | 2020-05-22 | Byondis B.V. | Humanized anti-sirpa antibodies |
| WO2020176790A1 (en) * | 2019-02-27 | 2020-09-03 | Fred Hutchinson Cancer Research Center | Hydrogel compositions and methods for treatment of malignancies |
| CN113784984A (en) * | 2019-03-04 | 2021-12-10 | 齐鲁普吉湾生物治疗公司 | anti-SIRP alpha antibodies |
| BR112021024003A2 (en) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Cancer treatment methods with sirp alpha-fc fusion in combination with an immune checkpoint inhibitor |
| JP2022535286A (en) | 2019-06-07 | 2022-08-05 | エーエルエックス オンコロジー インコーポレイテッド | Methods and reagents for reducing interference of drugs that bind CD47 in serological assays |
| EP3756688A1 (en) | 2019-06-25 | 2020-12-30 | Université de Nantes | Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection |
| JP7295283B2 (en) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | FLT3L-FC fusion proteins and methods of use |
| CN112867507A (en) * | 2019-08-20 | 2021-05-28 | 科望(苏州)生物医药科技有限公司 | Novel anti-SIRPA antibodies |
| CN114555123B (en) | 2019-10-18 | 2024-04-02 | 四十七公司 | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| EP4065101A1 (en) | 2019-11-27 | 2022-10-05 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN111116713B (en) * | 2020-01-07 | 2023-06-23 | 郑州大学 | Sirpa protein affinity cyclic peptide and application thereof |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| BR112022017136A2 (en) | 2020-02-28 | 2022-10-11 | Tallac Therapeutics Inc | CONJUGATION mediated by transglutaminase |
| JP2023504675A (en) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding molecules for cancer treatment |
| US20220401516A1 (en) | 2020-06-01 | 2022-12-22 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| KR20230106645A (en) | 2020-11-11 | 2023-07-13 | 다이이찌 산쿄 가부시키가이샤 | Combination of antibody-drug conjugate with anti-SIRPα antibody |
| WO2022110922A1 (en) | 2020-11-30 | 2022-06-02 | 启愈生物技术(上海)有限公司 | ANTI-SIRPα ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| US20220363779A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| CN117355539A (en) * | 2021-05-28 | 2024-01-05 | 百奥泰生物制药股份有限公司 | anti-SIRP alpha antibody and application thereof |
| CA3218692A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
| AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (en) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Diacylglycerol Kinase Modulating Compounds |
| AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CR20230585A (en) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Diacylglyercol kinase modulating compounds |
| TW202317190A (en) | 2021-06-29 | 2023-05-01 | 美商思進公司 | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
| WO2023020459A1 (en) | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | MONOCLONAL ANTIBODY TARGETING SIRPα AND USE THEREOF |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| WO2023094698A1 (en) | 2021-11-29 | 2023-06-01 | Ose Immunotherapeutics | Specific antagonist anti-sirpg antibodies |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (en) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| TW202400138A (en) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d modulating compounds |
| US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US20100215640A1 (en) * | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| CA2702217A1 (en) * | 2007-10-11 | 2009-04-16 | Jayne Danska | Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| CN101780283A (en) * | 2010-03-16 | 2010-07-21 | 中国人民解放军第二军医大学 | Application of signal adjusting protein alpha in preparation of DC vaccine for preventing and treating tumors |
| CN101880324B (en) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | Monoclonal antibody of anti-human SIRPalpha, cell strain, preparation method and application thereof |
| JP6606505B2 (en) * | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Anti-SIRPα antibody and bispecific macrophage enhancing antibody |
-
2017
- 2017-04-14 AU AU2017248626A patent/AU2017248626A1/en active Pending
- 2017-04-14 SG SG11201808465UA patent/SG11201808465UA/en unknown
- 2017-04-14 CN CN201780023581.2A patent/CN109071664B/en active Active
- 2017-04-14 BR BR112018070823A patent/BR112018070823A2/en unknown
- 2017-04-14 CA CA3020373A patent/CA3020373A1/en active Pending
- 2017-04-14 PE PE2018001974A patent/PE20181921A1/en unknown
- 2017-04-14 WO PCT/EP2017/059071 patent/WO2017178653A2/en active Application Filing
- 2017-04-14 EA EA201891882A patent/EA201891882A1/en unknown
- 2017-04-14 EP EP17718881.0A patent/EP3443010A2/en active Pending
-
2018
- 2018-10-10 CO CONC2018/0010855A patent/CO2018010855A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017178653A2 (en) | 2017-10-19 |
| CN109071664B (en) | 2023-02-21 |
| WO2017178653A3 (en) | 2018-07-05 |
| CN109071664A (en) | 2018-12-21 |
| CO2018010855A2 (en) | 2018-11-13 |
| PE20181921A1 (en) | 2018-12-11 |
| CA3020373A1 (en) | 2017-10-19 |
| AU2017248626A1 (en) | 2018-10-11 |
| EP3443010A2 (en) | 2019-02-20 |
| BR112018070823A2 (en) | 2019-02-05 |
| EA201891882A1 (en) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808465UA (en) | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201908542QA (en) | Gip receptor activating peptide | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201807949WA (en) | Engineered immunoglobulins with altered fcrn binding | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201908918WA (en) | Novel pyridazinone herbicides | |
| SG11201809223PA (en) | Erbb inhibitors and uses thereof | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201908825TA (en) | Stable multispecific antibodies | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs |